


ATC codes: **L01DB01**

|                          |   |
|--------------------------|---|
| Indication               | Follicular lymphoma <span>ICD11 code: <b>2B50.Z</b></span>  |
| INN                      | Doxorubicin   |
| Medicine type            | Chemical agent  |
| List type                | Complementary   |
| Formulations             | Parenteral > General injections > IV: 10 mg in vial (hydrochloride) ; 50 mg in vial (hydrochloride)   |
| EML status history       | First added in 2015 ( <b>TRS 994</b> )  |
| Sex                      | All   |
| Age                      | Adolescents and adults  |
| Therapeutic alternatives | The recommendation is for this specific medicine  |
| Patent information       | Patents have expired in most jurisdictions<br>Read more <a href="#">about patents</a> .  |

Tags

Cancer

Wikipedia

[Doxorubicin](#) 

DrugBank

[Doxorubicin](#) 

### Summary of evidence and Expert Committee recommendations

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for doxorubicin on the complementary list of the EML for use in treatment protocols for follicular lymphoma was specifically endorsed. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for follicular lymphoma is attached.

[Expert Committee report](#) 

